|
Neximmune ، Inc. (NEXI) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
NexImmune, Inc. (NEXI) Bundle
قم بتقييم شركة NexImmune، Inc. (NEXI) التوقعات المالية مثل الخبير! تأتي حاسبة DCF (NEXI) هذه مع بيانات مالية مملوءة مسبقًا وتوفر لك المرونة لتعديل نمو الإيرادات و WACC والهوامش والافتراضات الأساسية الأخرى لتتماشى مع توقعاتك.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -20.4 | -27.1 | -52.4 | -61.6 | -28.2 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .4 | .6 | .9 | 1.5 | 1.0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -20.9 | -27.7 | -53.3 | -63.1 | -29.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 10.1 | 5.0 | 81.8 | 34.6 | 4.6 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.2 | 2.8 | 1.0 | 2.4 | 1.3 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -1.2 | -.9 | -2.4 | -1.3 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -20.6 | -29.4 | -54.1 | 518.9 | -29.2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -20.3 | -28.0 | -57.3 | 520.4 | -29.2 | -1.3 | .0 | .0 | .0 | .0 |
| WACC, % | 9.48 | 9.5 | 9.5 | 7.91 | 9.5 | 9.18 | 9.18 | 9.18 | 9.18 | 9.18 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -1 | |||||||||
| Net Debt | -3 | |||||||||
| Equity Value | 2 | |||||||||
| Diluted Shares Outstanding, MM | 1 | |||||||||
| Equity Value Per Share | 1.82 |
What You Will Get
- Comprehensive NEXI Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Real-Time Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess NexImmune’s future prospects.
- User-Friendly Design: Designed for industry professionals yet easy to navigate for newcomers.
Key Features
- 🔍 Real-Life NEXI Financials: Pre-filled historical and projected data for NexImmune, Inc. (NEXI).
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate NexImmune’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize NexImmune’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review NexImmune’s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for NexImmune, Inc. (NEXI)?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for NexImmune.
- Flexible Inputs: Modify yellow-highlighted fields to explore different financial scenarios.
- In-Depth Analysis: Automatically computes NexImmune’s intrinsic value and Net Present Value.
- Preloaded Information: Historical and projected data provide reliable starting points for analysis.
- Expert-Level Tool: Perfect for financial analysts, investors, and business consultants focusing on biotech.
Who Should Use This Product?
- Individual Investors: Gain insights to make informed decisions about purchasing or selling NexImmune, Inc. (NEXI) stock.
- Financial Analysts: Enhance valuation methodologies with comprehensive financial models tailored for NexImmune, Inc. (NEXI).
- Consultants: Provide clients with accurate and timely valuation analyses related to NexImmune, Inc. (NEXI).
- Business Owners: Learn how biopharmaceutical companies like NexImmune, Inc. (NEXI) are valued to inform your own business strategies.
- Finance Students: Explore valuation principles using case studies and data from NexImmune, Inc. (NEXI).
What the NexImmune Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations specific to NexImmune.
- Real-World Data: NexImmune’s historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics relevant to NexImmune.
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable results tailored to NexImmune's data.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.